Company Analysis

Lexeo Therapeutics, Inc. (LXEO)

Nasdaq: LXEO · Biological Products, (No Diagnostic Substances) · New York, NY · filing with the SEC since 2022
Grade4.6
◀ Past 4.2● Present 4.5▶ Future 4.9
6 est.

Who runs Lexeo Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Townsend Richard Nolan
Chief Executive Officer. First filing Nov 2023, latest Sep 28, 2026, 19 filings in all.
Officers reporting now
7
of 15 people with a filing in the last fifteen months
Directors reporting now
8
18 people on the record since 2023
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Townsend Richard NolanChief Executive OfficerNov 2023Sep 28, 20268 · $700,000
Tamayo Louis EdwardChief Financial OfficerAug 2025Sep 28, 20262 · $0.00
Otero Jose ManuelChief Operating OfficerMay 2024Sep 28, 20267 · $100,000
Bhalla Narinder PalChief Medical OfficerFeb 2026Sep 28, 20261 · $100,000
Adler EricChief Medical OfficerNov 2023Nov 20, 20253 · $0.00
Robertson JennyChief Legal OfficerNov 2023Nov 20, 20253 · $0.00
See Tai SandiChief Development OfficerFeb 2024Nov 20, 20253 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Agger Mette KirstinedirectorNov 2023Jun 29, 2026none
Altschuler StevendirectorNov 2023Jun 29, 2026none
Cholmondeley Paula HdirectorNov 2023Jun 29, 2026none
Cooperstone BrendadirectorNov 2023Jun 29, 2026none
Diaz Reinaldo MdirectorNov 2023Jun 29, 2026none
Tanguler TolgadirectorNov 2024Jun 29, 2026none
Van Hauwermeiren TimothydirectorJul 2024Jun 29, 2026none
Sepp-Lorenzino LauradirectorApr 2026Apr 30, 2026none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton LXEO · research, not advice